Phastar acted as the Independent Data Analysis Centre (IDAC) for a Phase III trial in thrombotic microangiopathy (TMA) after HSCT. With 13 DMC meetings, ad hoc analyses, and tight budget constraints, our team ensured secure data sharing, expert review, and streamlined workflows—delivering high-quality results while controlling costs.
Download the full case study to explore the approach, outcomes, and lasting impact.
